Evidence map›Paper›PMID 34375782›Full record

ArticleVirology2021

Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.

Zach Menne, Vasilis C Pliasas, Richard W Compans, Sheniqua Glover, Constantinos S Kyriakis, Ioanna Skountzou

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zach MenneDepartment of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA; Centers for Excellence in Influenza Research and Surveillance, Emory-UGA Center, Atlanta, GA, USA.
Vasilis C PliasasCenters for Excellence in Influenza Research and Surveillance, Emory-UGA Center, Atlanta, GA, USA; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, USA.
Richard W CompansDepartment of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA; Centers for Excellence in Influenza Research and Surveillance, Emory-UGA Center, Atlanta, GA, USA.
Sheniqua GloverDepartment of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, USA.
Constantinos S KyriakisCenters for Excellence in Influenza Research and Surveillance, Emory-UGA Center, Atlanta, GA, USA; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, USA.
Ioanna SkountzouDepartment of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30322, USA; Centers for Excellence in Influenza Research and Surveillance, Emory-UGA Center, Atlanta, GA, USA. Electronic address: iskount@emory.edu.
Auburn University · USEmory University · US

Funding

Skin Vaccination Against Influenza in the Young And AgedR01AI110680 · NIAID · EMORY UNIVERSITY · PI COMPANS, RICHARD W · 2015 to 2019
$3.9M
NIAID NIH HHS HHSN272201400004CNIAID NIH HHS N01 AI070006NIAID NIH HHS R01 AI110680
6 · The paper itself

Abstract

Neuraminidase (NA) is the second most abundant glycoprotein on the surface of influenza A viruses (IAV). Neuraminidase type 1 (NA1) based virus-like particles (VLPs) have previously been shown to protect against challenge with H1N1 and H3N2 IAV. In this study, we produced neuraminidase type 2 (NA2) VLPs derived from the sequence of the seasonal IAV A/Perth/16/2009. Intramuscular vaccination of mice with NA2 VLPs induced high anti-NA serum IgG levels capable of inhibiting NA activity. NA2 VLP vaccination protected against mortality in a lethal A/Hong Kong/1/1968 (H3N2) virus challenge model, but not against lethal challenge with A/California/04/2009 (H1N1) virus. However, bivalent vaccination with NA1 and NA2 VLPs demonstrated no antigenic competition in anti-NA IgG responses and protected against lethal challenge with H1N1 and H3N2 viruses. Here we demonstrate that vaccination with NA VLPs is protective against influenza challenge and supports focusing on anti-NA responses in the development of future vaccination strategies.

Indexed as

AnimalsDisease Models, AnimalDose-Response Relationship, ImmunologicImmunity, HeterologousImmunoglobulin GInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesInjections, IntramuscularMiceNeuraminidaseOrthomyxoviridae InfectionsVaccinationVaccines, CombinedVaccines, Virus-Like ParticleViral ProteinsImmunoglobulin GInfluenza VaccinesNA protein, influenza A virusNeuraminidaseVaccines, CombinedVaccines, Virus-Like ParticleViral ProteinsInfluenza virusInfluenza virus vaccineNeuraminidase (NA)Virus-like particle (VLP)

Identifiers

PMID34375782
PMCPMC8479372
OpenAlexW3187658727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.